Table 1. Current pharmacologic phase 2/3 clinical trials for the treatment of pediatric nonalcoholic fatty liver disease.
| Phase and
ClinicalTrials.gov identifier |
Category | Proposed mechanism of action | |
|---|---|---|---|
| Curcumin | Phase 2
NCT04109742 |
Antioxidant | Decrease inflammation |
| Empaglifozin | Phase 2
NCT03867487 |
Sodium-glucose co-transporter
2 (SGLT2) inhibitor |
Decrease insulin resistance |
| Losartan | Phase 2
NCT03467217 |
Angiotensin II receptor blocker | Reduces plasminogen activator
inhibitor-1 (PAI-1) production and improves insulin sensitivity |
| IMM-124E | Phase 2
NCT03042767 |
A bovine colostrum enriched
with anti-lipopolysaccharide (LPS) antibodies |
Reduces transfer of LPS from
gut; anti-inflammatory |
| Elafibranor | Phase 2
NCT03883607 |
Peroxisome proliferator-
activated receptor (PPAR) α/δ agonist |
Improves insulin sensitivity and
lipid metabolism and reduces inflammation |